Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 4/2014

01-05-2014 | Review

Effect of pharmacotherapy for anxiety disorders on quality of life: a meta-analysis

Auteurs: Stefan G. Hofmann, Jade Q. Wu, Hannah Boettcher, Jamie Sturm

Gepubliceerd in: Quality of Life Research | Uitgave 4/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

Pharmacotherapy is an effective treatment for anxiety disorders, but its effects on quality of life (QOL) have not been examined systematically. Our objective was to conduct an effect size analysis of pharmacological interventions on QOL outcomes in patients with DSM-IV anxiety disorders.

Methods

Manual and electronic searches using PubMed, PsycINFO, and the Cochrane Library were conducted for records from the first available date through May 1, 2013 for trials of pharmacological interventions in patients with anxiety disorders, which had measures of QOL before and after treatment. Of 1,865 entries, 93 studies were identified as potentially relevant and 32 met inclusion criteria, of which results were examined from 22 studies reporting 27 distinct pharmacological trials, representing data from 4,344 anxiety disorder patients. Data were extracted independently by multiple observers to estimate within-group and placebo-controlled random effects of the treatment changes on QOL. We hypothesized that pharmacotherapy improves QOL, which is associated with improvement in anxiety symptoms.

Results

Pharmacological interventions effectively improved QOL from before to after treatment (Hedges’ g = 0.59), although the controlled effect size is smaller among those trials with placebo interventions (Hedges’ g = 0.32). These effect sizes were robust, increased with publication year, and increased with reductions in anxiety symptoms.

Conclusions

Pharmacological therapy is effective for improving QOL in anxiety disorders, and larger symptom reductions are associated with greater improvement in QOL.
vorige artikel Quality of life in overweight and obese children and adolescents: a literature review
volgende artikel Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery
Literatuur
1.
Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617–627.PubMedCentralPubMedCrossRef
2.
DuPont, R. L., Rice, D. P., Miller, L. S., Shiraki, S. S., Rowland, C. R., & Harwood, H. J. (1996). Economic costs of anxiety disorders. Anxiety, 2(4), 167–172.PubMedCrossRef
3.
Cramer, V., Torgersen, S., & Kringlen, E. (2005). Quality of life and anxiety disorders: A population study. Journal of Nervous and Mental Disease, 193(3), 196–202.PubMedCrossRef
4.
Mendlowicz, M. V., & Stein, M. B. (2000). Quality of life in individuals with anxiety disorders. American Journal of Psychiatry, 157(5), 669–682.PubMedCrossRef
5.
Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2007). Quality of life in the anxiety disorders: A meta-analytic review. Clinical Psychology Review, 27(5), 572–581.PubMedCrossRef
6.
Rapaport, M. H., Clary, C., Fayyad, R., & Endicott, J. (2005). Quality-of-life impairment in depressive and anxiety disorders. American Journal of Psychiatry, 162(6), 1171–1178.PubMedCrossRef
7.
Spitzer, R. L., Kroenke, K., Linzer, M., Hahn, S. R., Williams, J. B., Brody, D., et al. (1995). Health-related quality of life in primary care patients with mental disorders. Journal of the American Medical Association, 274(19), 1511–1517.PubMedCrossRef
8.
Sherbourne, C. D., Wells, K. B., & Judd, L. L. (1996). Functioning and well-being of patients with panic disorder. American Journal of Psychiatry, 153(2), 213–218.PubMed
9.
Angermeyer, M. C., & Kilian, R. (2006). Theoretical models of quality of life for mental disorders. In H. Katschnig, H. Freeman, & N. Sartorius (Eds.), Quality of life in mental disorders (2nd ed.). Chichester: Wiley.
10.
Gyani, A., Shafran, R., Layard, R., & Clark, D. M. (2013). Enhancing recovery rates: Lessons from year one of IAPT. Behaviour Research and Therapy, 51(9), 597–606.PubMedCentralPubMedCrossRef
11.
Frisch, M. B. (1998). Quality of life therapy and assessment in health care. Clinical Psychology: Science and Practice, 5(1), 19–40.
12.
Gladis, M. M., Gosch, E. A., Dishuk, N. M., & Crits-Christoph, P. (1999). Quality of life: Expanding the scope of clinical significance. Journal of Consulting and Clinical Psychology, 67(3), 320–331.PubMedCrossRef
13.
Cohen, J. (1968). Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. Psychological Bulletin, 70(4), 213.PubMedCrossRef
14.
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., et al. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials, 17(1), 1–12.PubMedCrossRef
15.
Rosenthal, R. (1991). Meta-analytic procedures for social research (revised ed.). Thousand Oaks, CA: Publications Inc.
16.
Rosenthal, R., & Rubin, D. B. (1988). [Selection models and the file drawer problem]: Comment: Assumptions and procedures in the file drawer problem. Statistical Science, 3(1), 120–125.CrossRef
17.
18.
19.
Hedges, L. V., & Olkin, I. (1985). Statistical methods for meta-analysis. New York: Academic Press.
20.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Erlbaum.
21.
Rosenthal, R. (1993). Meta-analytic procedures for social research. Newbury Park, CA: Sage Publications.
22.
Hedges, L. V., & Vevea, J. L. (1998). Fixed- and random-effects models in meta-analysis. Psychological Methods, 3(4), 486–504.CrossRef
23.
Moses, L. E., Mosteller, F., & Beuhler, J. H. (2002). Comparing results of large clinical trials to those of meta-analyses. Statistics in Medicine, 21(6), 793–800.PubMedCrossRef
24.
Borenstein, M., Hedges, L. V., Higgins, J., & Rothstein, H. (2005). Comprehensive meta-analysis, version 2. Englewood, NJ: Biostat Inc.
25.
Ball, S. G., Kuhn, A., Wall, D., Shekhar, A., & Goddard, A. W. (2005). Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: A double-blind, prospective comparison between paroxetine and sertraline. Journal of Clinical Psychiatry, 66(1), 94–99.PubMedCrossRef
26.
Beşiroğlu, L., Uğuz, F., Yilmaz, E., Ağargün, M., Aşkin, R., & Aydin, A. (2008). Psychopharmacological treatment and quality of life in obsessive compulsive disorder. Turkish Journal of Psychiatry, 19(1), 38.PubMed
27.
Blank, S., Lenze, E. J., Mulsant, B. H., Dew, M. A., Karp, J. F., Shear, M. K., et al. (2006). Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. Journal of Clinical Psychiatry, 67(3), 468–472.PubMedCrossRef
28.
Blaya, C., Seganfredo, A. C., Dornelles, M., Torres, M., Paludo, A., Heldt, E., et al. (2007). The efficacy of milnacipran in panic disorder: An open trial. International Clinical Psychopharmacology, 22(3), 153.PubMedCrossRef
29.
Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., et al. (2000). Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. Journal of the American Medical Association, 283(14), 1837–1844.PubMedCrossRef
30.
Bruce, L. C., Heimberg, R. G., Blanco, C., Schneier, F. R., & Liebowitz, M. R. (2012). Childhood maltreatment and social anxiety disorder: Implications for symptom severity and response to pharmacotherapy. Depression and Anxiety, 29(2), 132–139.PubMedCentralCrossRef
31.
Davidson, J. R., Bose, A., & Wang, Q. (2005). Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Journal of Clinical Psychiatry, 66(11), 1441.PubMedCrossRef
32.
Davidson, J., Baldwin, D., Stein, D. J., Kuper, E., Benattia, I., Ahmed, S., et al. (2006). Treatment of posttraumatic stress disorder with venlafaxine extended release: A 6-month randomized controlled trial. Archives of General Psychiatry, 63(10), 1158.PubMedCrossRef
33.
Dougherty, D. D., Jameson, M., Deckersbach, T., Loh, R., Thompson-Hollands, J., Jenike, M., et al. (2009). Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive–compulsive disorder. International Clinical Psychopharmacology, 24(6), 306–311.PubMedCrossRef
34.
Francois, C., Montgomery, S. A., Despiegel, N., Roiz, J., & Auguier, P. (2008). Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention with generalised anxiety disorder. International Journal of Clinical Practice, 62(11), 1693–1702.PubMedCentralPubMedCrossRef
35.
Koran, L. M., Bromberg, D., Hornfeldt, C. S., Shepski, J. C., Wang, S., & Hollander, E. (2010). Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Comprehensive Psychiatry, 51(4), 373–379.PubMedCrossRef
36.
Liebowitz, M. R., DeMartinis, N. A., Weihs, K., Londborg, P. D., Smith, W. T., Chung, H., et al. (2003). Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 64(7), 785–792.PubMedCrossRef
37.
Krystal, J. H., Rosenheck, R. A., Cramer, J. A., Vessicchio, J. C., Jones, K. M., Vertrees, J. E., et al. (2011). Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD. Journal of the American Medical Association, 306(5), 493.PubMedCrossRef
38.
McRae, A. L., Brady, K. T., Mellman, T. A., Sonne, S. C., Killeen, T. K., Timmerman, M. A., et al. (2004). Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety, 19(3), 190–196.PubMedCrossRef
39.
Menza, M. A., Dobkin, R. D., & Marin, H. (2007). An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. Journal of Clinical Psychopharmacology, 27(2), 207–210.PubMedCrossRef
40.
Muehlbacher, M., Nickel, M. K., Nickel, C., Kettler, C., Lahmann, C., Gil, F. P., et al. (2005). Mirtazapine treatment of social phobia in women: A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 25(6), 580–583.PubMedCrossRef
41.
Pollack, M. H., Endicott, J., Liebowitz, M., Russell, J., Detke, M., Spann, M., et al. (2008). Examining quality of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatment. Journal of Psychiatric Research, 42(12), 1042.PubMedCrossRef
42.
Simon, N. M., Kaufman, R. E., Hoge, E. A., Worthington, J. J., Herlands, N. N., Owens, M. E., et al. (2009). Open-label support for duloxetine for the treatment of panic disorder. CNS Neuroscience & Therapeutics, 15(1), 19–23.CrossRef
43.
Stahl, S. M., Gergel, I., & Li, D. (2003). Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 64(11), 1322.PubMedCrossRef
44.
Tenney, N. H., Denys, D. A., van Megen, H. J., Glas, G., & Westenberg, H. G. (2003). Effect of a pharmacological intervention on quality of life in patients with obsessive–compulsive disorder. International Clinical Psychopharmacology, 18(1), 29–33.PubMedCrossRef
45.
van Apeldoorn, F. J., Timmerman, M. E., Mersch, P. P., van Hout, W. J., Visser, S., van Dyck, R., et al. (2010). A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: Treatment results through 1-year follow-up. Journal of Clinical Psychiatry, 71(5), 574.PubMedCrossRef
46.
Zhang, J., Hongbing, X., & Zhiqing, C. (2013). Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder. Experimental and Therapeutic Medicine, 5(3), 840.PubMedCentralPubMed
47.
Frisch, M. B., Clark, M. P., Rouse, S. V., Rudd, M. D., Paweleck, J. K., Greenstone, A., et al. (2005). Predictive and treatment validity of life satisfaction and the Quality of Life Inventory. Assessment, 12(1), 66–78.PubMedCrossRef
48.
WHOQOL Group. (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychological Medicine, 28(3), 551–558.CrossRef
49.
Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin, 29(2), 321–326.PubMed
50.
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(20), 22–33.PubMed
51.
EuroQol Group. (1990). EuroQol—A new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
52.
Jenkinson, C., Layte, R., & Lawrence, K. (1997). Development and testing of the Medical Outcomes Study 36-item short form health survey summary scale scores in the United Kingdom: Results from a large-scale survey and a clinical trial. Medical Care, 35(4), 410–416.PubMedCrossRef
53.
Ware, J. E., Jr, & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.PubMedCrossRef
54.
Hay, R. D., Sherbourne, C. D., & Mazel, R. M. (1993). The RAND 36-Item Health Survey 1.0. Health Economics, 2(3), 217–227.CrossRef
55.
Oliver, J. P. J., Huxley, P., Bridges, K., & Mohamad, H. (1996). Quality of life and mental health services. London: Routledge.
56.
König, H. H., Born, A., Günther, O., Matschinger, H., Heinrich, S., Riedel-Heller, S. G., et al. (2010). Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders. Health and Quality of Life Outcomes, 8, 47.PubMedCentralPubMedCrossRef
57.
Wyrwich, K., Harnam, N., Revicki, D. A., Locklear, J. C., Svedsäter, H., & Endicott, J. (2009). Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire. International Clinical Psychopharmacology, 24(6), 289–295.PubMedCrossRef
58.
McAlinden, N. M., & Oei, T. P. (2006). Validation of the Quality of Life Inventory for patients with anxiety and depression. Comprehensive Psychiatry, 47(4), 307–314.PubMedCrossRef
59.
Hambrick, J. P., Turk, C. L., Heimberg, R. G., Schneier, F. R., & Liebowitz, M. R. (2004). Psychometric properties of disability measures among patients with social anxiety disorder. Journal of Anxiety Disorders, 18(6), 825–839.PubMedCrossRef
60.
Lehrer, J. (2010). The decline effect and the scientific method: The truth wears off. New Yorker, p. 52.
61.
Schooler, J. (2011). Cosmic habituation [Radio broadcast]. In E. Horne (Producer), Radiolab. New York: WNYC.
62.
63.
Hofmann, S. G., Asnaani, A., Vonk, J. J., Sawyer, A. T., & Fang, A. (2012). The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognitive Therapy and Research, 36(5), 427–440.PubMedCentralPubMedCrossRef
64.
Safren, S. A., Heimberg, R. G., Brown, E. G., & Holle, C. (1997). Quality of life in patients with social phobia. Depression and Anxiety, 4(3), 126–133.CrossRef
65.
Telch, M. J., Schmidt, N. B., Jaimez, T. L., Jacquin, K. M., & Harrington, P. J. (1995). Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. Journal of Consulting and Clinical Psychology, 63(5), 823–830.PubMedCrossRef
Metagegevens
Titel
Effect of pharmacotherapy for anxiety disorders on quality of life: a meta-analysis
Auteurs
Stefan G. Hofmann
Jade Q. Wu
Hannah Boettcher
Jamie Sturm
Publicatiedatum
01-05-2014
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 4/2014
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-013-0573-8

Andere artikelen Uitgave 4/2014

Quality of Life Research 4/2014 Naar de uitgave

Review

Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery

OriginalPaper

Masticatory factors as predictors of oral health-related quality of life among elderly people in Kaohsiung City, Taiwan

OriginalPaper

Gender-specific quality of life after cancer in young adulthood: a comparison with the general population

OriginalPaper

Health-related quality of life among breast, prostate, and colorectal cancer patients with end-stage disease

OriginalPaper

Validation of a Quality of Life Questionnaire for Bronchiectasis: psychometric analyses of the Spanish QOL-B-V3.0

OriginalPaper

Psychometric properties of the PROMIS® pediatric scales: precision, stability, and comparison of different scoring and administration options